# 2015 Inter-governmental Working Meeting on Drug Compounding and Drug Supply Chain Security

U.S. Food and Drug Administration White Oak Campus, Great Room 10903 New Hampshire Avenue Silver Spring, Maryland 20993

# **AGENDA**

Monday, November 16, 2015 8:00 AM – 5:00 PM	
Drug Compounding	
8:00 AM – 9:00 AM	Registration
9:00 AM – 9:15 AM	Welcome and Introduction Stephen Ostroff, Acting Commissioner of Food and Drugs
9:15 AM – 10:30 AM	<ul> <li>Compounding Regulatory Policy Update</li> <li>Jane Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research, FDA and Agency Lead on Compounding</li> <li>Q&amp;A/Comments</li> </ul>
10:30 AM – 10:45 AM	Break
10:45 AM – 12:15 PM	<ul> <li>Draft Standard Memorandum of Understanding between FDA and the States</li> <li>Jane Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research, FDA and Agency Lead on Compounding</li> <li>Beth Ferguson, Deputy Director, Minnesota Board of Pharmacy</li> <li>Kimberly Grinston, Executive Director, Missouri Board of Pharmacy</li> <li>Q&amp;A/Comments</li> </ul>
12:15 PM – 1:30 PM	Lunch
1:30 PM – 2:30 PM	<ul> <li>Information Sharing and Disclosure</li> <li>Sarah Kotler, Director, Division of Freedom of Information, Office of the Commissioner, FDA</li> <li>Lauren DiPaola, Testimony Specialist, Office of Policy and Risk Management, Office of Regulatory Affairs, FDA</li> <li>Daniel Kelber, Associate General Counsel, Illinois Department of Financial and Professional Regulation</li> <li>Caroline Juran, Executive Director, Virginia Board of Pharmacy</li> <li>Q&amp;A/Comments</li> </ul>
2:30 PM – 2:45 PM	Break

#### 2:45 PM - 4:15 PM

# A Comparison of U.S. Pharmacopeial Convention General Chapter 797 to the **Current Good Manufacturing Practice Regulations Enforced by FDA**

- Ian Deveau, Branch Chief, Office of Compliance, Office of Manufacturing Quality, Division of Drug Quality I, Global Compliance Branch 1, FDA
- Q&A/Comments

#### 4:15 PM - 4:45 PM

## **Listening Session**

Opportunity for states to share their views with FDA

#### 4:45 PM - 5:00 PM

## **Closing Remarks**

Brian Kehoe, Acting Director of Intergovernmental Affairs, FDA

#### Tuesday, November 17, 2015

9:00 AM - 4:45 PM

## 9:00 AM - 9:15 AM

## **Welcome and Opening Remarks**

Jane Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research, FDA and Agency Lead on Compounding

### 9:15 AM - 10:45 AM

## **Inspections of Sterile Compounding Facilities and Enforcement**

- Ellen Morrison, Assistant Commissioner for Operations, Office of Regulatory Affairs, FDA
- Mike Levy, Deputy Director for Policy and Analysis, Office of Compliance, Center for Drug Evaluation and Research, FDA
- Anthony Rubinaccio, Executive Director, New Jersey Board of Pharmacy
- Tera McConnell, Compliance Program Officer, Texas State Board of Pharmacy
- Q&A/Comments

## 10:45 AM - 11:00 AM **Break**

## 11:00 AM – 12:00 PM State Handling of Outsourcing Facilities

- Carmen Catizone, Executive Director, National Association of Boards of Pharmacy
- Virginia Herold, Executive Officer, California State Board of Pharmacy
- Allison Dudley, Executive Director, Florida Board of Pharmacy
- Michael Dupuis, Executive Director, New Hampshire Board of Pharmacy
- Q&A/Comments

#### 12:00 PM - 1:00 PM

Lunch

## **Drug Supply Chain Security**

#### 1:00 PM - 1:15 PM

#### **Welcome and Introduction**

Howard Sklamberg, Deputy Commissioner for Global Regulatory Operations and Policy, FDA

#### 1:15 PM – 1:30 PM

## **Overview of DSCSA Implementation**

- Ilisa Bernstein, Deputy Director, Office of Compliance, Center for Drug Evaluation and Research, FDA
- Q&A/Comments

## 1:30 PM - 3:15 PM

# Wholesale Distributor and Third-Party Logistics (3PL) Provider Licensing

- Melissa Kim, Regulatory Counsel, Office of Drug Security, Integrity, and Response, Office of Compliance, Center for Drug Evaluation and Research, FDA
- Diane Goyette, Regulatory Counsel, Medical Products and Tobacco Policy Staff, Office of Policy and Risk Management, Office of Regulatory Affairs, FDA
- Virginia Herold, Executive Officer, California Board of Pharmacy
- Renee Alsobrook, Compliance & Enforcement Manager, Florida Department of Business and Professional Regulation
- Cindy Hamilton, Chief Compliance Officer, Oklahoma Board of Pharmacy
- Q&A/Comments

#### 3:15 PM - 3:30 PM

#### Break

#### 3:30 PM - 4:15 PM

#### **FDA and State Collaboration**

- Eleni Anagnostiadis, Division Director, Division of Drug Supply Chain Integrity, Office of Drug Security, Integrity, and Response, Office of Compliance, Center for Drug Evaluation and Research, FDA
- Lauren DiPaola, Testimony Specialist, Office of Regulatory Affairs, FDA
- Caroline Juran, Executive Director, Virginia Board of Pharmacy
- Fiona Karbowicz, Pharmacist Consultant, Oregon Board of Pharmacy
- Q&A/Comments

## 4:15 PM - 4:30 PM

# **Open Microphone**

#### 4:30 PM - 4:45 PM

## **Closing Remarks**

Ilisa Bernstein, Deputy Director, Office of Compliance, Center for Drug Evaluation and Research, FDA